• Home
  • NEW DAY MEDICINE
  • 4 (90) 2026
  • 27 -4 (90) 2026 - Boltayeva G.I., Yaxshiyeva M.F. - CONTEMPORARY APPROACHES TO THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH ENDOMETRIAL HYPERPLASIA

27 -4 (90) 2026 - Boltayeva G.I., Yaxshiyeva M.F. - CONTEMPORARY APPROACHES TO THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH ENDOMETRIAL HYPERPLASIA

CONTEMPORARY APPROACHES TO THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH ENDOMETRIAL HYPERPLASIA

Boltayeva G.I. - Tashkent State Medical University

Yaxshiyeva M.F. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Endometrial hyperplasia is a pathological proliferation of the uterine lining, characterized by either diffuse or focal enlargement of the glandular and stromal components, with a predominance of glandular proliferation. Endometrial hyperplasia (EH), which clinically manifests as abnormal uterine bleeding, is one of the most common reasons for women of reproductive and perimenopausal age to seek specialized gynecological care. In recent years, there has been a noticeable trend toward a decrease in the age at primary diagnosis of this pathology, reflected in an increasing number of EH cases among younger women.

Keywords: endometrial hyperplasia, hysteroscopy, abnormal uterine bleeding, infertility, hormonal therapy, recurrence of endometrial hyperplasia, endometrial cancer.

First page

185

Last page

189

For citation:Boltayeva G.I., Yaxshiyeva M.F. - CONTEMPORARY APPROACHES TO THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH ENDOMETRIAL HYPERPLASIA //New Day in Medicine 4(90)2026 185-189 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

  1. Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. Obstet Gynecol. 2022;140(6):1061-1075. doi:10.1097/AOG.0000000000004989.
  2. Kubyshkin AV, Aliev LL, Fomochkina II, Kovalenko YP, Litvinova SV, Filonenko TG, et al. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia. Inflamm Res. 2016;65(10):785-794. doi:10.1007/s00011-016-0960-z.
  3. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022;306(2):407-421. doi:10.1007/s00404-021-06380-5.
  4. Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019;58(3):342-352. doi:10.1080/0284186X.2018.1540886.
  5. Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020;126(12):2775-2783. doi:10.1002/cncr.32822.
  6. Габидуллина Р.И., Смирнова Г.А., Нухбала Ф.Р., Валеева Е.В., Орлова Ю.И., Шакиров А.А. Гиперпластические процессы эндометрия: современная тактика ведения пациенток. Гинекология. 2019;21(6):53-58.
  7. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):e8. doi:10.3802/jgo.2016.27.e8.
  8. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232-254. doi:10.1093/humupd/dmw042.
  9. Yang JH, Chen CD, Chen SU, Yang YS, Chen MJ. Factors influencing the recurrence potential of benign endometrial polyps after hysteroscopic polypectomy. PLoS One. 2015;10(12):e0144857. doi:10.1371/journal.pone.0144857.
  10. Tanos V, Berry KE, Seikkula J, Abi Raad E, Stavroulis A, Sleiman Z, et al. The management of polyps in female reproductive organs. Int J Surg. 2017;43:7-16. doi:10.1016/j.ijsu.2017.05.012.

    file

    download